-
Exchange of experience
-
Exchange of ideas/insights
-
Discuss interpretation of regulatory guidance
-
Discuss difficulties encountered in daily QP practice and how to solve them
-
Inform each other on country specific items (import, export, views of regulatory authorities)
-
Any other goals that the members may bring in
-
Try to influence HA by providing valuable input to new legislation
-
Installing core team dealing with new legislation would be an asset.
|
 |
|
Dr Susanne Ding, Boehringer Ingelheim, Germany
|
|
 |
|
Niina Taylor, Pfizer, UK
|
|
 |
|
Patryk Jegorow, Takeda, Ireland
|
|
 |
|
Katrien Himpens, Janssen Pharmaceutica NV, Belgium
|
|
 |
|
It is with our deepest sadness to inform you of the sudden and unexpected passing of our dear colleague and friend Justin Barry. Justin was a highly valued member of the IMP QP Board since 2013, representing the voice of a Qualified Person from a small biotech company.
We will remember Justin being always in good mood and humor, reflective, inspiring, outstandingly helpful and accommodating, always available when needed. We are deeply grateful for the time together.
|
|
|
Administration work is provided by the EQPA Secretary. To become member of the IMP Working Group please contact us via eMail: